Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

Anaplastic lymphoma kinase (ALK) rearrangements were first implicated as driving mutations in non-small cell lung cancer in 2007. Since then, a number of novel, small-molecule inhibitors directed against the ALK receptor have demonstrated superiority over standard chemotherapies in the treatment of...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2018-09, Vol.38 (9), p.4969-4975
Main Authors: Millett, Ralph L, Elkon, Jacob M, Tabbara, Imad A
Format: Article
Language:English
Subjects:
Cancer
Central nervous system
Clinical trials
Lung cancer
Lymphoma
Medical research
Metastases
Mutation
Non-small cell lung carcinoma
Penetration resistance
Protein-tyrosine kinase
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anaplastic lymphoma kinase (ALK) rearrangements were first implicated as driving mutations in non-small cell lung cancer in 2007. Since then, a number of novel, small-molecule inhibitors directed against the ALK receptor have demonstrated superiority over standard chemotherapies in the treatment of ALK rearrangement-positive lung cancer. Of considerable importance when considering such therapies is the ability of each to overcome mutations conferring acquired resistance, as well as penetrate the central nervous system (CNS), the most common site of metastasis and traditionally the most difficult to breach. Herein is a review of the efficacy, indications, and degree of CNS penetration for the ALK-targeting agents crizotinib, ceretinib, alectinib, brigatinib, and lorlatinib, as well as a summary of ongoing clinical trials comparing these drugs.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.12815